Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T17:52:17.196Z.
Calculation as of: 2026-10-06T17:52:17.196Z.
Quote observation: 2026-10-06T17:50:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a3d1fbdfc20658083391a22a35257b501cad1354629c31eed1b40f8a69f1a870
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Lucid Diagnostics Inc.
Market Cap
$113.89M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.06M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$114.57M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$111.94M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.69M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.51M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$115.76M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$112.69M
Operating Cash Flow Yield
N/A
TTM Avg
66.47%
3Y Avg
66.47%
5Y Avg
66.47%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $113.89M | N/A | N/A | N/A | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $114.06M | N/A | N/A | N/A | N/A |
| Genelux Corporation (GNLX)vs › | $114.57M | N/A | N/A | N/A | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | N/A | N/A | N/A | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $111.94M | N/A | N/A | N/A | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | N/A | N/A | N/A | N/A |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.51M | N/A | N/A | N/A | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.76M | N/A | N/A | N/A | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.69M | N/A | 66.47% | 66.47% | 66.47% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.31M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
